Obesity

797

Review clinical trials related to Obesity. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesity

Background: Obesity affects 1 in 5 children in the United States. Childhood obesity often persists into adolescence and adulthood. It can also raise the risk of sleep apnea, fatty liver disease, and fluid buildup in the brain and lead to early-onset puberty. This natural history study will explore how factors such as genes, hormones, diet, and chemical exposures affect puberty in children with obesity. Objective: To learn which factors predict the early start of puberty in children with obesity vs those of normal weight. Eligibility: Children aged 5 to 7 years with obesity or of normal weight. Design: Participants will have clinic visits every 6 months until they reach age 12. Each clinic visit will include these tests and procedures: A physical exam. Collection of blood, urine, and saliva samples. Some samples will be used for genetic tests. Questions about medical history and medications and supplements. A questionnaire about their physical activity over the previous week. A silicone wrist band. Participants will wear a soft wristband for a week prior to each visit. It will tell researchers what chemicals the children were exposed to during that time. Breast ultrasound, for girls. A gel will be applied, and a wand will be pressed against the skin. The wand uses sound waves to see the tissue inside the breast. DXA whole body scan. Once a year, participants will have a DXA (dual energy X-ray absorptiometry) scan. This scan measures the amount of bone, muscle, and fat in the body. Optional food diary. Parents may record everything the participant eats for two 24-hour periods ...

Participants needed: 400
Trial details
Age: 5-12Biological sex: AllType: ObservationalSponsor: National Institute of Environmental Health Sciences (NIEHS)Updated: Aug 21, 2026Locations: 1
Eligibility criteria

Stated willingness to comply with all study procedures and availability for the... [+3]

Known diagnosis of syndromic/genetic form of obesity [+4]

Status: Recruiting

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

Participants needed: 900
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Eli Lilly and CompanyUpdated: Aug 21, 2026Locations: 187
Eligibility criteria

Are on stable incretin therapy at screening [+7]

Have a prior or planned surgical treatment for obesity (liposuction, cryolipolys... [+11]

Status: Not yet recruiting

Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adults

Background: Diabetes and obesity are chronic diseases. They can affect blood flow and how the body processes nutrients, and complications over time can lead to early death. Diabetes can affect children as well as adults, but the disease seems to be more severe and to progress faster when it appears in younger people. Researchers want to understand more about how diabetes and obesity develop and change over time. Objective: To collect data and samples regularly from people with obesity and diabetes. Eligibility: People aged 8 to 65 years. They must be overweight or obese; or have high blood sugar; or have problems with how their body uses food for energy. Design: Participants will have additional procedures during routine care visits at the NIH clinic. Data collected for the study will include the following: Information from the participant s medical chart will be kept for research. Questionnaires will ask about participant s eating habits, feelings, sleep, and substance use. They will take 30 to 60 minutes. Care providers will address any issues revealed in these surveys. Blood, saliva, urine, and stool samples will be collected. Samples may be used for genetic tests. Data and samples will be kept for future research. Participants may remain in the study up to 30 years.

Participants needed: 1,000
Trial details
Age: 8-65Biological sex: AllType: ObservationalSponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Updated: Aug 21, 2026Locations: 1
Eligibility criteria

Age 8 years to 65 years

History of significant medical illnesses that the investigators feel may interfe... [+2]

Status: Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.

Participants needed: 1,980
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Eli Lilly and CompanyUpdated: Aug 21, 2026Locations: 162
Eligibility criteria

30 kilogram per square meter (kg/m2) OR [+6]

Have a prior or planned surgical treatment for obesity (liposuction, cryolipolys... [+9]

Status: Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

Participants needed: 1,035
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Eli Lilly and CompanyUpdated: Aug 21, 2026Locations: 159
Eligibility criteria

Have type 2 diabetes [+3]

Have a prior or planned surgical treatment for obesity (liposuction, cryolipolys... [+13]

Status: Recruiting

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.

Participants needed: 200
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Eli Lilly and CompanyUpdated: Aug 21, 2026Locations: 42
Eligibility criteria

Have type 2 diabetes [+7]

Have any form of diabetes other than type 2 diabetes [+17]

Status: Recruiting

Intensive Weight Loss Intervention Versus Bariatric Surgery for Adults With Severe and Complex Obesity: the LightBAR Randomised Trial

With this trial, the aim is to assess the benefits and harms of a non-surgical intensive weight loss intervention that includes total dietary replacements, behavioural support and weight-loss medication compared with bariatric surgery for people with severe and complex obesity. The interpretation of the results will help inform future care pathways for people with obesity in whom bariatric surgery is currently the only available effective treatment option.

Participants needed: 500
Trial details
Age: 18-60Biological sex: AllType: InterventionalSponsor: Carsten DirksenUpdated: Aug 21, 2026Locations: 14
Eligibility criteria

Aged 18 to 60 years (inclusive) at time of screening. [+4]

Prior bariatric or hiatal surgery, not including intragastric balloons or duoden... [+10]

Status: Not yet recruiting

Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity

Background: Obesity and related illnesses cause at least 2.8 million deaths each year worldwide. Few treatments exist for obesity that are safe and widely available. A study drug (mirabegron \[MG\]) combined with a supplement (alpha-lipoic acid \[ALA\]) may help. Objective: To learn how MG and ALA can help the body process food. Eligibility: People aged 18 to 65 years with a body mass index between 30 and 45 kg/m2. Design: Participants will be screened. They will have a physical exam. They will have blood and urine tests and a test of their heart function. They will speak with a dietician. The study has two phases. Each phase begins with a 2-day stay in the clinic; then the participant will take the study drugs at home for about 4 weeks, followed by another 2-day stay in the clinic. They will also have outpatient visits about 2 weeks after each clinic stay. During the clinic stays, participants will undergo many tests: They will have a plastic tube (catheter) inserted into a vein in each arm. These will be used to draw blood and to infuse glucose (sugar) and insulin. They will have imaging scans. They will have a clear hard plastic shield placed over their head to measure oxygen and carbon dioxide as they breathe. Participants will take the study drugs at home. Both MG and ALA are taken by mouth with water. During one phase, participants will take MG plus a placebo. A placebo looks like the study drug but doesn t contain medicine....

Participants needed: 60
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Updated: Aug 21, 2026Locations: 1
Eligibility criteria

Adults 18 to 65 years of age [+1]

Hypersensitivity and associated allergic reactions to mirabegron or alpha-lipoic... [+27]

Status: Recruiting

The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action

Ovwerweight and obesity prevalence in persons with T1D has increased, which further complicates management and risk for complications. The proposed study is relevant to public health because it helps us understand the role of the gut microbiome in disease pathophysiology in T1D youth with overweight and obesity as well as potential mechanisms to modify disease.

Participants needed: 114
Trial details
Phase: Phase 2Age: 11-18Biological sex: AllType: InterventionalSponsor: Heba M. IsmailUpdated: Aug 21, 2026Locations: 1
Eligibility criteria

Overweight/obese youth 11-18 years of age with T1D at time of enrollment. [+1]

Known monogenic forms of diabetes or Type 2 diabetes (confirmed clinically and b... [+5]

Status: Recruiting

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

This study is open to adults between 18 and 74 years of age and who have a body mass index (BMI) of 30 kg/m2 or more, or a BMI of 27 kg/m2 or more and at least 1 health problem related to their weight. People who have previously not managed to lose weight by changing their diet can participate. People with type 2 diabetes cannot take part in this study. The purpose of this study is to find out whether a medicine called BI 3034701 helps people living with obesity or overweight to lose weight. This study has 7 groups of participants. Groups 1 to 6 get different doses of BI 3034701; Group 7 gets placebo. Placebo looks like BI 3034701 but does not contain any medicine. Every participant has more than an 80% chance of getting BI 3034701. Participants receive 2 injections of BI 3034701 or placebo under their skin for 42 weeks. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 10 months. During this time, they visit the study site 15 times. The study doctors regularly measure the participants' body weight and take necessary laboratory tests. Participants also answer questions about their well-being and note their food intake and physical activity in diaries. The results will be compared between groups of participants to see whether the treatment works. The study doctors also regularly check participants' health and take note of any unwanted effects.

Participants needed: 300
Trial details
Phase: Phase 2Age: 18-74Biological sex: AllType: InterventionalSponsor: Boehringer IngelheimUpdated: Aug 20, 2026Locations: 55
Eligibility criteria

Male or female, age ≥18 to <75 years at the time of signing informed consent, an... [+5]

Body weight increase or decrease (self-reported) of greater than 5% in the 3 mon... [+7]

Status: Recruiting

Longitudinal Study of the Psychological Impact of Bariatric Surgery

This prospective observational study evaluates the effect of bariatric surgery on mental health and hair cortisol in patients with morbid obesity over a 3-year follow-up. Assessments will be performed before surgery and at 1 month, 1 year, 2 years, and 3 years to analyze psychological changes, weight changes, and the need for psychological support.

Participants needed: 70
Trial details
Age: 18-70Biological sex: AllType: ObservationalSponsor: University of AlicanteUpdated: Aug 21, 2026Locations: 2Duration: 3 Years
Eligibility criteria

Men and women aged 18 to 70 years who are candidates for gastric bypass, sleeve...

Patients with previous bariatric surgery and pregnant women during follow-up wil...

Status: Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight

The main purpose of this study is to find out how significantly Eloralintide slows stomach emptying in participants who are overweight or obese. For each participant, the study will last approximately 21 weeks and will include 2 overnight stays in the clinical research unit (CRU) lasting between 4 and 8 days. There will be 13 other visits.

Participants needed: 56
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Eli Lilly and CompanyUpdated: Aug 20, 2026Locations: 2
Eligibility criteria

Have overweight or obesity, but are otherwise overtly healthy. [+2]

Have been diagnosed with Type 1 or Type 2 diabetes mellitus, or have either of t... [+5]

Status: Recruiting

Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments

Background: Heart disease is a leading cause of death. People can reduce their heart disease risk by exercising more. Mobile health technology may make people more successful at increasing their exercise. This includes things like physical activity monitors and smartphone apps. Objective: To find out if mobile health technology can increase physical activity. Eligibility: African American women ages 21-75 who: * Are overweight or obese * Live in certain areas near Washington, DC * Have a smartphone that can use the study app Design: At visit 1, participants will * Answer survey questions. These may be about medical history, physical activity, and weight. They may also cover body image, health perception, and spirituality. * Have body size measured and get blood tests * Get a device to wear on the wrist. It will record physical activity and hours of sleep. * Learn how to download and use the study mobile app For 2 weeks, researchers will collect data about participants physical activity. Then participants will have a study visit with additional blood tests. All participants will get messages from the app that encourage exercise. Some participants will get data from the app about exercise near their home or work. Some participants may get face-to-face coaching. Participants may get wireless devices. These measure body weight, blood pressure, and blood glucose. Participants can measure these at home and upload the data to the app for the study. Participants will have visits after 3 and 6 months. They will repeat the visit 1 tests. ...

Participants needed: 325
Trial details
Age: 21-75Biological sex: FemaleType: InterventionalSponsor: National Heart, Lung, and Blood Institute (NHLBI)Updated: Aug 19, 2026Locations: 1
Eligibility criteria

Medical condition, including heart failure, recent unintentional weight loss or... [+11]

Status: Not yet recruiting

A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

The purpose of this study is to evaluate the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adult participants living with obesity or overweight with or without T2DM.

Participants needed: 351
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: AstraZenecaUpdated: Aug 20, 2026Locations: 49
Eligibility criteria

Adult participant aged 18 years or older at the time of informed consent. [+5]

T1DM [+5]

Status: Not yet recruiting

Negative Pressure Wound Therapy Devices in Total Knee Arthroplasty

This study is a single-center, prospective, randomized, open-label clinical trial evaluating three commercially available closed-incision negative pressure wound therapy (ciNPWT) devices: NPseal, PICO, and Prevena, in adult patients undergoing primary total knee arthroplasty (TKA) who meet predefined high-risk criteria for wound complications. A total of approximately 300 participants will be enrolled and randomized in a 1:1:1 fashion to receive one of the three study dressings applied over the closed surgical incision at the end of the procedure. All participants will otherwise receive standard perioperative and postoperative care. The primary follow-up period will extend through 90 days after surgery. The primary objective is to compare the incidence of 90-day surgical site complications, including superficial infection, wound dehiscence, seroma, and hematoma, across the three dressing groups. Secondary objectives include evaluation of device usability, patient experience, and device-related issues (such as loss of seal, alarms, tubing or pump problems, fluid saturation, and premature dressing changes), as well as assessment of the interaction between skin closure method and device performance. Research-specific activities are limited to eligibility confirmation, informed consent, randomization, administration of a brief postoperative patient survey at approximately postoperative day 7 and/or dressing removal, provider assessment of the dressing at removal, and collection of clinical outcomes from the medical record. No additional blood draws, imaging, or invasive procedures are required for participation. This study is designed to address a gap in the literature by providing head-to-head comparative data on commonly used ciNPWT systems in a high-risk primary TKA population, with the goal of informing postoperative wound management strategies in clinical practice.

Participants needed: 300
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: The Cleveland ClinicUpdated: Aug 18, 2026
Eligibility criteria

Age 18 years or older [+6]

Prisoners [+3]

Status: Not yet recruiting

A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity

The main objective of this trial is to establish the bioequivalence of survodutide in a pre-filled syringe (reference product \[formulation A\]) and in a vial (test product \[formulation B2\]) in male and female trial participants who are healthy or otherwise healthy with overweight/obesity, following subcutaneous administration.

Participants needed: 44
Trial details
Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: Boehringer IngelheimUpdated: Aug 18, 2026Locations: 1
Eligibility criteria

Male or female trial participant who is healthy or otherwise healthy with overwe... [+4]

Any finding in the medical examination (including BP, PR or ECG) deviating from... [+4]

Status: Recruiting

A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity

This study is being done to look at the efficacy single and multiple ascending dose study investigating safety, tolerability, pharmacokinetics, food effect and target engagement in healthy adults including a single cohort in adults living with obesity. Participants will either get NNC6022-0004, (the treatment being tested) or Placebo (a treatment that has no active medicine in it) and which treatment participants get is decided by chance.

Participants needed: 128
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Novo Nordisk A/SUpdated: Aug 19, 2026Locations: 1
Eligibility criteria

Male, or female of non-childbearing potential. [+4]

Known or suspected hypersensitivity to study intervention(s) or similar products... [+12]

Status: Recruiting

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have HFpEF or HFmrEF and excess body weight. Participants will get NNC0487-0111 or placebo by injection once a week. Which treatment participants get is decided by chance. NNC0487-0111 is a new medicine that doctors cannot prescribe yet, but it has been tested in people before.

Participants needed: 5,610
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Novo Nordisk A/SUpdated: Aug 18, 2026Locations: 838
Eligibility criteria

Body Mass Index (BMI) greater than or equal to (>=) 30 kilograms per square metr... [+1]

MI, stroke, unstable angina pectoris or worsening HF leading to either hospitali... [+6]

Status: Recruiting

A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-INHBE in adult participants with obesity (in Part 1), the safety, tolerability, PK, and PD of multiple doses of ARO-INHBE either as monotherapy, or in combination with tirzepatide, in adult participants with obesity with and without type 2 diabetes mellitus (in Part 2 and Part 3).

Participants needed: 180
Trial details
Phase: Phase 1, Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Arrowhead PharmaceuticalsUpdated: Aug 18, 2026Locations: 7
Eligibility criteria

Obesity, defined as Body Mass Index (BMI) between 30 to 50 kilograms (kg)/square... [+5]

Self-reported (or documented) weight gain or loss >5% within 3 months prior to S... [+8]

Status: Recruiting

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even those who start chemotherapy at a healthy weight. This study is being done to find out if caloric restriction achieved by a personalized nutritional menu and exercise plan during routine chemotherapy can make the patient's ALL more sensitive to chemotherapy and also reduce the amount of body fat gained during treatment. The goals of this study are to help make chemotherapy more effective in treating the patient's leukemia as demonstrated by fewer patients with leukemia minimal residual disease (MRD) while also trying to reduce the amount of body fat that chemotherapy causes the patient to gain in the first month.

Participants needed: 240
Trial details
Phase: Phase 2Age: 7-25Biological sex: AllType: InterventionalSponsor: Etan OrgelUpdated: Aug 19, 2026Locations: 16
Eligibility criteria

Patients must be ≥ 7.0 and <26.0 years of age. [+7]

Patient will be excluded if they are underweight at time of enrollment (BMI% <5t... [+8]

Status: Recruiting

The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity

The purpose of this study is to determine the effect of tirzepatide on vasomotor symptoms and on measures of biological aging.

Participants needed: 40
Trial details
Phase: Phase 4Age: 46-60Biological sex: FemaleType: InterventionalSponsor: Mayo ClinicUpdated: Aug 18, 2026Locations: 1
Eligibility criteria

Females [+7]

Current or recent use (past 4 weeks) treatment with menopausal hormone therapy. [+21]

Status: Recruiting

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

Background: Researchers use mixed meal tolerance tests (MMTTs) to look at how people s bodies respond to eating a meal. However, researchers do not agree on how to decide the number of calories to give in each meal. Some use fixed meals, which are the same size for everyone, and some use adjusted meals, based on the size of the person s body. Researchers want to know which MMTT is best to use for future research. Objective: To learn how fixed vs adjusted meals affect blood glucose levels in healthy people. Eligibility: Healthy people aged 18 years or older. Design: Participants will have 3 or 4 clinic visits of up to 8 hours in 8 weeks. Participants will have baseline tests: Their height, weight, and waist size will be measured. They will have an oral glucose tolerance test: A needle attached to a tube (IV) will be inserted into a vein in the arm. They will have a sugary drink. Blood samples will be taken from the tube at intervals up to 3 hours after the drink. They will have a body scan. Participants will have 2 MMTT visits. One will include a fixed meal and one will include an adjusted meal. They will have tests at both visits: Resting metabolic rate: A clear hood will be placed over the participant s head while they rest for 20 minutes. This will measure the oxygen they breathe in and out. MMTT. Participants will have 5 minutes to drink a liquid meal. Blood samples will be taken at intervals for the next 4 hours....

Participants needed: 79
Trial details
Age: 18-99Biological sex: AllType: InterventionalSponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Updated: Aug 18, 2026Locations: 1
Eligibility criteria

Provision of signed and dated informed consent form. [+3]

Current use of medications, dietary supplements, or alternative therapies known... [+10]

Status: Not yet recruiting

Semaglutide in Youth With Autism Spectrum Disorder

This study is a 6-month, two-arm, RCT which will evaluate the effectiveness and safety of semaglutide in adolescents aged 12-18 years with autism spectrum disorder (ASD) and obesity. The primary outcome is change in body mass index (BMI, kg/m²) from baseline to Month 6. Secondary, descriptive outcomes are changes in metabolic parameters (e.g., lipid levels), side effects, and compliance with semaglutide.

Participants needed: 42
Trial details
Phase: Phase 4Age: 12-18Biological sex: AllType: InterventionalSponsor: Children's Hospital Medical Center, CincinnatiUpdated: Aug 18, 2026Locations: 1
Eligibility criteria

12-18 years of age [+6]

Healthworks patient who has lost >5% body weight over the past 3 months [+13]

Status: Recruiting

A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight

The purpose of this clinical study is to find out if UBT251 is safe and effective to be taken together with medicines, like midazolam, caffeine and warfarin in participants living with overweight or obesity.

Participants needed: 44
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Novo Nordisk A/SUpdated: Aug 18, 2026Locations: 1
Eligibility criteria

Male or female (sex assigned at birth, inclusive of all gender identities). [+4]

Known or suspected hypersensitivity to study intervention(s) or related products... [+5]

Status: Recruiting

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)

This study is being done to learn about the safety and effects of the study drugs, PF-08653945 and PF-08653944, when given alone or together for weight loss, compared to a placebo (a dummy drug that has no active ingredient in it).

Participants needed: 872
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: PfizerUpdated: Aug 17, 2026Locations: 65
Eligibility criteria

adults aged 18 years or older with [+2]